I could very well be wrong but you can't say that the majority of the market is wrong. Pharmasett was already red hot before it was acquired by Gilead. Gilead paid a big premium but the premium is 89%. Not 10 times the valuation of Pharmasett. MNKD can't seem to find a willing partner to market the drug for the price Al is asking for. I seriously doubt Al can sell the company without first proving the sales potential of the drug. This is where the problem lies. Al needs the capital to launch the drug in additional to the capital to get through approval. So rounds of dilution are unavoidable. As I said, Al can keep his portion of the pie the same by converting debt into shares. Retail investors like us will get smaller and smaller share of the pie. Will the smaller share of the pie worth more than what we pay for in the beginning?

I seriously doubt a company will pay 10 billion for MNKD before Al can achieve a robust sales growth. I am not saying it is impossible. It is just hard to imagine some company will risk betting on oral Insulin again until they are more confident that the bet is a winner or close to be one.

As to the claim of technosphere platform, I hope you realize that nothing is quick or cheap in the US pharma world. There is no late stage drug in the pipeline for technosphere. Anything significant will be years in the making. So what is the use of the platform anyway.